DHTKD1 and neoplasm: E1A deletions have also been used in two clinical trials of VCN-01, as this deletion prevents viral replication in cells with functional pRb, therefore improving tumour-selectivity (Bazan-Peregrino et al. 2021; Garcia-Carbonero et al. 2022).